Hyperkalemia is a serious complication of chronic kidney disease (CKD) that is associated with an increased risk of cardiovascular events and all-cause mortality. Dietary restriction of potassium, including from fruits and vegetables, is a longstanding aspect of hyperkalemia management supported by clinical guidelines. However, recent research has begun to question such dietary recommendations, and evidence on the association between hyperkalemia and dietary potassium is inconsistent. ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
There are few data on whether the survival benefit of kidney transplantation is different for men and women.
American Society of Nephrology leaders met with Congress to urge increased funding to support organ transplantation.
Opinions differ on the use of no anticoagulation versus regional citrate anticoagulation for treatment of AKI with CKRT.
We've all been guilted into ordering inpatient blood pressure meds. Tim Anderson, MD, asks, "Why?"
Interim analysis from the APPLAUSE-IgAN trial found favorable results for the use of iptacopan in IgAN.
A super-learner strategy gave accurate risk predictions of kidney failure and death for people with moderate to severe CKD.
Longer follow-up results of the RUBY-3 trial found povetacicept is well-tolerated and shows promise for IgAN treatment.
Researchers uncovered clinical and economic of the Kidney BEAM physical activity digital health intervention for CKD.
What can the Gila monster and mourning dove teach us about comparative nephrology?
Advertisement
Podcasts
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
We've all been guilted into ordering inpatient blood pressure meds. Tim Anderson, MD, asks, "Why?"
Review Dr. Burton Rose's writings on treatment options for hypovolemic states and hypovolemic shock.
In Print
Assessing recurrent gout risk, SARS-CoV-2 vaccine response during dialysis, plant-based diets with CKD, and more.
Special issue discusses racial inequity in living donor kidney transplant, teen BMI and CKD risk, and more
Conferences
The annual scientific, educational, and networking meeting of the International Society of Nephrology
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
The National Kidney Foundation's premier educational event covering advancements in all subspecialties of nephrology
The joint annual meeting of the American Society of Transplantation and the American Society of Transplant Surgeons
Expert Columns
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
